Commerciële zegetocht Myring gaat verder. Klein bier maar toch...
Mithra and Gynial Sign Commercialization Agreementfor Myring™ in Switzerland?
Mithra grants license for its vaginal contraceptive ringto Gynial for commercialization in Switzerland?Strengthening its partnership with Women’s Health specialist Gynial,already responsible for the Austrian market?Large-scaled global commercialization of Myring™ after first successful launches in Europe
Liege, Belgium,05 May 2020–7:30
CEST–Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into a license and supply agreement(LSA)with Gynial GmbH for the commercialization of its hormonal contraceptive ring Myring™ in Switzerland. Under the terms of this agreement, Gynial will distributeMyring™ in Switzerland, where the Swiss contraceptive rings market is worth EUR 8 million per year1. Mithrawill receive an upfront payment and recurring revenues based on an agreed licensing model.Moreover, Mithra will manufacture Myring™at its Contract Development and Manufacturing Organization facility in Belgium. This LSA is the second agreement signed with Gynial, following the one entered in 2017 for the commercialization of Myring™ in Austria. Gynial is an Austrian pharmaceutical company founded in 2007 with a key focus on Women’s Health, and on contraception in particular. To date, Mithra has licensed Myring™ to industry leaders in 31 countries, including the three biggest worldwide markets(United States, Germany and Italy). After the successful launch in Czech Republic, Belgium, Luxemburg and Germany, other launches should follow in Europe where Mithra has already obtained 21 out of 23 marketing authorizations.To meet the growing demand, the Mithra CDMO has increased its production capacity to nearly two million rings in 2020. Fromthe beginning of the health crisis caused by Covid-19, Mithra has managed to maintain the production and supplyof Myring™ on track, in compliancewith all the measures requiredby the Belgian authorities while ensuring the safety of its collaborators.François Fornieri, CEO Mithra Women’s Health, commented: “We are pleased to have finalized this second agreement withGynial, an excellent partner with whom welook forward to working with to commercialize our vaginal ring in both Swiss and Austrian markets.In this first half of the year marked by the Covid-19, we have worked very hard to ensure the pursuit of our activities, both in terms of R&D, production and financial management. All discussions and negotiations with potential commercial partners are currently being actively pursued and do not seem to be impacted in any way by the health crisis. This demonstratesa strong interest in our innovative products andsolid confidence in their potential in the growing women’s health market.”